Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338)

Susan A Fiscus, Andrea Kovacs, Leslie A Petch, Chengcheng Hu, Andrew A Wiznia, Lynne M Mofenson, Ram Yogev, Kenneth McIntosh, Stephen I Pelton, Sonia Napravnik, Kenneth Stanley, Sharon A Nachman, Susan A Fiscus, Andrea Kovacs, Leslie A Petch, Chengcheng Hu, Andrew A Wiznia, Lynne M Mofenson, Ram Yogev, Kenneth McIntosh, Stephen I Pelton, Sonia Napravnik, Kenneth Stanley, Sharon A Nachman

Abstract

Background: The association between baseline drug resistance mutations and subsequent increase in viral failure has not been established for HIV-infected children. We evaluated drug resistance mutations at 39 codon sites (21 protease inhibitor (PI) resistant codons and 18 nucleoside reverse transcriptase inhibitor (NRTI) resistant codons) for 92 clinically stable NRTI-experienced, PI-naive HIV-infected children 2 to 17 years of age who were initiating new therapy with ritonavir plus zidovudine (ZDV) and lamivudine or plus stavudine. The association between baseline drug resistance mutations and subsequent viral failure after 12 and 24 weeks of highly active antiretroviral therapy (HAART) was studied.

Results: There were few primary PI associated mutations in this PI-naïve population, but 84% had NRTI mutations--codons 215 (66%), 41 (42%), 67 (37%), 210 (33%) and 70 (32%). None of the specific baseline drug resistance mutations were associated with a higher rate of virologic failure after 12 or 24 weeks of HAART. Median week 12 viral load decreased as the total number of NRTI mutations at baseline increased (P = 0.006). Specifically, a higher level of baseline ZDV resistance mutation was associated with a decrease in viral failure after 12 weeks on a ZDV-containing HAART regimen (P = 0.017).

Conclusion: No increase was seen in the rate of viral failure after HAART associated with the presence of resistance mutations at baseline. This paradoxical result may be due to adherence, replicative capacity, or ZDV hypersusceptibility to the new regimen.

Figures

Figure 1
Figure 1
Association between the number of baseline nucleoside reverse transcriptase inhibitor mutations and viral load after 12 weeks on HAART (Viral load is the log10 RNA copies/mL value at 12 weeks.)

References

    1. Principi N, Marchisio P, Esposito S, Rossi P, Gattinara GC, Galli L, Gabiano C, Zuccotti GV, Orlandi P. Zidovudine therapy and HIV type 1 mutations in children with symptomatic HIV type 1 infection: effect of switching to didanosine or zidovudine plus didanosine therapy. AIDS Res Hum Retroviruses. 1998;14:1653–9.
    1. Eshleman SH, Krogstad P, Jackson JB, Wang YG, Lee S, Wei LJ, Cunningham S, Wantman M, Wiznia A, Johnson G, Nachman S, Palumbo P. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377) J Infect Dis. 2001;183:1732–8. doi: 10.1086/320728.
    1. Perez EE, Rose SL, Peyser B, Lamers SL, Burkhardt B, Dunn BM, Hutson AD, Sleasman JW, Goodenow MM. Human immunodeficiency virus type 1 protease genotype predicts immune and viral responses to combination therapy with protease inhibitors (PIs) in PI-naïve patients. J Infect Dis. 2001;183:579–88. doi: 10.1086/318538.
    1. Mullen J, Leech S, O'Shea S, Chrystie IL, du Mont G, Ball C, Sharland M, Cottam F, Zuckerman M, Rice P, Easterbrook P. Antiretroviral drug resistance among HIV-1 infected children failing treatment. J Med Virol. 2002;68:299–304. doi: 10.1002/jmv.10203.
    1. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CAB, Schapiro JM, Dellamonica P. Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomised controlled trial. Lancet. 1999;353:2195–9. doi: 10.1016/S0140-6736(98)12291-2.
    1. Shafer RW. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev. 2002;15:247–7. doi: 10.1128/CMR.15.2.247-277.2002.
    1. Shearer WT, Quinn TC, LaRussa P, Lew JF, Mofenson L, Almy S, Rich K, Handelsman E, Diaz C, Pagano M, Smeriglio V, Kalish LA. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. N Engl J Med. 1997;336:1337–42. doi: 10.1056/NEJM199705083361901.
    1. Mofenson LM, Korelitz J, Meyer WA, Bethel J, Rich K, Pahwa S, Moye J, Nugent R, Read J. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. J Infect Dis. 1997;175:1029–38.
    1. Nachman SA, Stanley K, Yogev R, Pelton S, Wiznia A, Lee S, Mofenson L, Fiscus S, Rathore M, Jimenez E, Borkowsky W, Pitt J, Smith ME, Wells B, McIntosh K. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. JAMA. 2000;283:492–8. doi: 10.1001/jama.283.4.492.
    1. Friedland GH, Williams A. Attaining higher goals in HIV treatment: the central importance of adherence. AIDS. 1999;13:S61–72.
    1. Bangsberg DR, Charlebois ED, Grant RM, Holodniy M, Deeks SG, Perry S, Conroy KN, Clark R, Guzman D, Zolopa A, Moss A. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS. 2003;17:1925–32. doi: 10.1097/00002030-200309050-00011.
    1. Walsh JC, Pozniak AL, Nelson MR, Mandalia S, Gazzard BG. Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance. JAIDS. 2002;30:278–87.
    1. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis. 2003;37:1112–8. doi: 10.1086/378301.
    1. Van Rompay KKA, Matthews TB, Higgins J, Canfield DR, Tarara RP, Wainberg MA, Schinazi RF, Pedersen NC, North TW. Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. J Virol. 2002;76:6083–92. doi: 10.1128/JVI.76.12.6083-6092.2002.
    1. Weber J, Chakraborty B, Weberova J, Miller MD, Quinones-Mateu ME. Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation. J Clin Microbiol. 2005;43:1395–400. doi: 10.1128/JCM.43.3.1395-1400.2005.
    1. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'thiacytodine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA. 1993;90:5653–6. doi: 10.1073/pnas.90.12.5653.
    1. Miranda LR, Gotte M, Liang F, Kuritzkes DR. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations. Antimicrob Agents Chemother. 2005;49:2648–56. doi: 10.1128/AAC.49.7.2648-2656.2005.
    1. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DD. Update of the drug resistance mutations in HIV-1:2004. Top HIV Med. 2004;12:119–24.
    1. Yeni PG, Hammer SM, Carpenter CCJ, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JSG, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Volberding PA. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2002;288:222–35. doi: 10.1001/jama.288.2.222.
    1. Dyer JR, Pilcher CD, Shepard R, Schock J, Eron JJ, Fiscus SA. Comparison of NucliSens and Roche Monitor assays for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 1999;37:447–9.
    1. Yen-Lieberman B, Brambilla D, Jackson B, Bremer J, Coombs R, Cronin M, Herman S, Katzenstein D, Leung S, Lin HJ, Palumbo P, Rasheed S, Todd J, Vahey M, Reichelderfer P. Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories. J Clin Microbiol. 1996;34:2695–701.
    1. Brambilla D, Leung S, Lew J, Todd J, Herman S, Cronin M, Shapiro DE, Bremer J, Hanson C, Hillyer GV, McSherry GD, Sperling RS, Coombs RW, Reichelderfer PS. Absolute copy number and relative change in determinations of human immunodeficiency virus type 1 RNA in plasma: effect of an external standard on kit comparisons. J Clin Microbiol. 1998;36:311–4.
    1. Hollander M, Wolfe DA. Nonparametric Statistical Methods. New York: John Wiley; 1999.
    1. Mantel N. Chi-square tests with one degree of freedom: extensions of the Mantel-Haenszel procedure. J Am Stat Assoc. 1963;58:690–700. doi: 10.2307/2282717.
    1. Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc. 1979;74:829–36. doi: 10.2307/2286407.
    1. Pocock SJ. Clinical trials with multiple outcomes: a statistical perspective on their design, analysis, and interpretation. Controlled Clin Trials. 1997;18:530–45. doi: 10.1016/S0197-2456(97)00008-1.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir